Search

Your search keyword '"Voillat, Laurent"' showing total 130 results
Start Over Author "Voillat, Laurent" Language english
130 results on '"Voillat, Laurent"'

1. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Author

Dartigeas, Caroline, Quinquenel, Anne, Ysebaert, Loïc, Dilhuydy, Marie-Sarah, Anglaret, Bruno, Slama, Borhane, Le Du, Katell, Tardy, Stéphanie, Tchernonog, Emmanuelle, Orfeuvre, Hubert, Voillat, Laurent, Guidez, Stéphanie, Malfuson, Jean-Valère, Dupuis, Sandrine, Deslandes, Marine, Feugier, Pierre, and Leblond, Véronique

Published
2024
Full Text
View/download PDF

2. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

Author

Jachiet, Vincent, Ricard, Laure, Hirsch, Pierre, Malard, Florent, Pascal, Laurent, Beyne-Rauzy, Odile, Peterlin, Pierre, Maria, Alexandre Thibault Jacques, Vey, Norbert, D’Aveni, Maud, Gourin, Marie-Pierre, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, Terriou, Louis, De Renzis, Benoit, Durot, Eric, Natarajan-Ame, Shanti, Vekhoff, Anne, Voillat, Laurent, Park, Sophie, Vinit, Julien, Dieval, Céline, Dellal, Azeddine, Grobost, Vincent, Willems, Lise, Rossignol, Julien, Solary, Eric, Kosmider, Olivier, Dulphy, Nicolas, Zhao, Lin Pierre, Adès, Lionel, Fenaux, Pierre, Fain, Olivier, Mohty, Mohamad, Gaugler, Béatrice, and Mekinian, Arsène

Published
2023
Full Text
View/download PDF

3. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Author

Mekinian, Arsene, Zhao, Lin Pierre, Chevret, Sylvie, Desseaux, Kristell, Pascal, Laurent, Comont, Thibaut, Maria, Alexandre, Peterlin, Pierre, Terriou, Louis, D’Aveni Piney, Maud, Gourin, Marie-Pierre, Vey, Norbert, Rauzy, Odile Beyne, Grobost, Vincent, Bezanahary, Holy, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, De Renzis, Benoit, Durot, Eric, Natarajan-Amé, Shanti, Voillat, Laurent, Chermat, Fatiha, Lemaire, Karine, Jachiet, Vincent, Himberlin, Chantal, Thépot, Sylvain, Diaz, Jose Miguel Torregrosa, Frenzel, Laurent, Gyan, Emmanuel, Denis, Guillaume, Hirsch, Pierre, Kosmider, Olivier, Ades, Lionel, Fain, Olivier, and Fenaux, Pierre

Published
2022
Full Text
View/download PDF

4. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Author

Schavgoulidze, Anaïs, Talbot, Alexis, Perrot, Aurore, Cazaubiel, Titouan, Leleu, Xavier, Manier, Salomon, Buisson, Laure, Mahéo, Sabrina, Do Souto Ferreira, Laura, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Avet-Loiseau, Hervé, and Corre, Jill

Published
2023
Full Text
View/download PDF

5. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Author

Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, and Leleu, Xavier

Published
2022
Full Text
View/download PDF

6. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Author

Cazaubiel, Titouan, Leleu, Xavier, Perrot, Aurore, Manier, Salomon, Buisson, Laure, Maheo, Sabrina, Do Souto Ferreira, Laura, Lannes, Romain, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Schavgoulidze, Anais, Avet-Loiseau, Herve, and Corre, Jill

Published
2022
Full Text
View/download PDF

7. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Author

Lemonnier, François, Safar, Violaine, Beldi-Ferchiou, Asma, Cottereau, Anne-Ségolène, Bachy, Emmanuel, Cartron, Guillaume, Fataccioli, Virginie, Pelletier, Laura, Robe, Cyrielle, Letourneau, Audrey, Missiaglia, Edoardo, Fourati, Slim, Moles-Moreau, Marie-Pierre, Delmer, Alain, Bouabdallah, Reda, Voillat, Laurent, Becker, Stéphanie, Bossard, Céline, Parrens, Marie, Casasnovas, Olivier, Cacheux, Victoria, Régny, Caroline, Camus, Vincent, Delfau-Larue, Marie-Hélène, Meignan, Michel, de Leval, Laurence, Gaulard, Philippe, and Haioun, Corinne

Published
2021
Full Text
View/download PDF

8. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Author

Tondeur, Sylvie, Paul, Franciane, Riou, Jérémie, Mansier, Olivier, Ranta, Dana, Le Clech, Lenaïg, Lippert, Eric, Tavitian, Suzanne, Chaoui, Driss, Mercier, Mélanie, De Renzis, Benoit, Cottin, Laurane, Cassinat, Bruno, Chrétien, Jean-Marie, Ianotto, Jean-Christophe, Allangba, Olivier, Marzac, Christophe, Voillat, Laurent, Boyer, Françoise, Orvain, Corentin, Hunault-Berger, Mathilde, Girodon, François, Kiladjian, Jean-Jacques, Ugo, Valérie, and Luque Paz, Damien

Published
2021
Full Text
View/download PDF

9. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

10. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Author

Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, and Avet-Loiseau, Herve

Published
2016
Full Text
View/download PDF

11. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Author

Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, and Avet-Loiseau, Hervé

Published
2015
Full Text
View/download PDF

12. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Author

Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, and Avet-Loiseau, Herve

Published
2015
Full Text
View/download PDF

13. What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Author

Perrot, Aurore, Decaux, Olivier, Royer, Bruno, Caillot, Denis, Belhadj Merzoug, Karim, Farge, Agathe, Frenzel, Laurent, Sonntag, Cécile, Slama, Bohrane, Bourgeois-Petit, Emmanuelle, Moreau, Philippe, Voillat, Laurent, Luycx, Odile, Benboubker, Lotfi, Pica, Gian-Matteo, Maloisel, Frederic, Eveillard, Jean-Richard, Algrin, Caroline, Schmitt, Anna, Garlantézec, Ronan, Texier, Nathalie, Germain, Raphael, Willaime, Marion, and Hulin, Cyrille

Published
2022
Full Text
View/download PDF

15. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Author

Corre, Jill, Perrot, Aurore, Caillot, Denis, Belhadj, Karim, Hulin, Cyrille, Leleu, Xavier, Mohty, Mohamad, Facon, Thierry, Buisson, Laure, Do Souto, Laura, Lannes, Romain, Dufrechou, Stephanie, Prade, Naïs, Orsini-Piocelle, Frederique, Voillat, Laurent, Jaccard, Arnaud, Karlin, Lionel, Macro, Margaret, Brechignac, Sabine, Dib, Mamoun, Sanhes, Laurence, Fontan, Jean, Clement-Filliatre, Lauriane, Marolleau, Jean-Pierre, Minvielle, Stephane, Moreau, Philippe, and Avet-Loiseau, Hervé

Published
2021
Full Text
View/download PDF

16. Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients

Author

Corre, Jill, Perrot, Aurore, Caillot, Denis, Belhadj, Karim, Hulin, Cyrille, Leleu, Xavier, Mohty, Mohamad, Facon, Thierry, Buisson, Laure, Do Souto, Laura, Lannes, Romain, Dufrechou, Stephanie, Prade, Nais, Orsini-Piocelle, Frédérique, Voillat, Laurent, Jaccard, Arnaud, Karlin, Lionel, Macro, Margaret, Brechignac, Sabine, Dib, Mamoun, Sanhes, Laurence, Fontan, Jean, Filliatre‐Clement, Lauriane, Marolleau, Jean Pierre, Minvielle, Stephane, Moreau, Philippe, Avet-Loiseau, Hervé, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Henri Mondor, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Institut François Magendie, Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université Sorbonne Paris Cité (USPC), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des Maladies du Sang [CHU Lille] (SMS), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Centre Hospitalier Chalon-sur-Saône William Morey, CHU Limoges, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Saint Jean de Perpignan, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Bernardo, Elizabeth, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Service des Maladies du Sang [CHRU Lille], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Despite tremendous improvements in the outcome of patients with multiple myeloma (MM) in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if del(17p) is associated with TP53 mutations, the so-called "double-hit" population. To validate this finding, we designed a much larger study on 121 patients presenting del(17p) in >55% of their plasma cells, and homogeneously treated by an intensive approach. For these 121 patients, we performed deep next generation sequencing targeted on TP53. The outcome was then compared to a large control population (2505 patients lacking del(17p)). Our results confirmed that the "double hit" situation is the worst (median survival = 36 months), but that del(17p) alone also confers a poor outcome compared with the control cohort (median survival = 52.8 months vs 152.2 months, respectively). In conclusion, our study clearly confirms the extremely poor outcome of patients displaying "double hit", but also that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.

Published
2020

17. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Author

Facon, Thierry, Mary, Jean Yves, Hulin, Cyrille, Benboubker, Lotfi, Attal, Michel, Pegourie, Brigitte, Renaud, Marc, Harousseau, Jean Luc, Guillerm, Gaëlle, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Maisonneuve, Hervé, Troncy, Jacques, Dorvaux, Véronique, Monconduit, Mathieu, Martin, Claude, Casassus, Philippe, Jaubert, Jérôme, Jardel, Henry, Doyen, Chantal, Kolb, Brigitte, Anglaret, Bruno, Grosbois, Bernard, Yakoub-Agha, Ibrahim, Mathiot, Claire, and Avet-Loiseau, Hervé

Published
2007
Full Text
View/download PDF

19. Single versus double autologous stem-cell transplantation for multiple myeloma

Author

Attal, Michel, Harousseau, Jean-Luc, Facon, Thierry, Guilhot, Francois, Doyen, Chantal, Fuzibet, Jean-Gabriel, Monconduit, Mathieu, Hulin, Cyrille, Caillot, Denis, Bouabdallah, Reda, Voillat, Laurent, Sotto, Jean-Jacques, Grosbois, Bernard, and Bataille, Regis

Subjects
Multiple myeloma -- Care and treatment, Hematopoietic stem cells -- Evaluation, Hematopoietic stem cells -- Transplantation
Abstract

Patients with multiple myeloma may benefit from receiving two autologous stem-cell transplants instead of one, according to a study of 399 patients. Patients who received two stem cell transplants had better outcomes and lived longer than those who received one stem cell transplant. An autologous transplant means the patient donated his or her own cells to be used in the transplant.

Published
2003

21. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

Author

Moreau, Philippe, Hullin, Cyrille, Garban, Frédéric, Yakoub-Agha, Ibrahim, Benboubker, Lotfi, Attal, Michel, Marit, Gérald, Fuzibet, Jean-Gabriel, Doyen, Chantal, Voillat, Laurent, Berthou, Christian, Ketterer, Nicolas, Casassus, Philippe, Monconduit, Mathieu, Michallet, Mauricette, Najman, Albert, Sotto, Jean-Jacques, Bataille, Régis, and Harousseau, Jean-Luc

Published
2006
Full Text
View/download PDF

22. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Author

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, and Harousseau, Jean-Luc

Published
2012
Full Text
View/download PDF

23. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

Author

Yakoub-Agha, Ibrahim, Mary, Jean-Yves, Hulin, Cyrille, Doyen, Chantal, Marit, Gérald, Benboubker, Lotfi, Voillat, Laurent, Moreau, Philippe, Berthou, Christian, Stoppa, Anne-Marie, Maloisel, Frédéric, Rodon, Philippe, Dib, Mamoun, Pegourie, Brigitte, Casassus, Philippe, Slama, Borhane, Damaj, Ghandi, Zerbib, Robert, Harousseau, Jean-Luc, Mohty, Mohamad, and Facon, Thierry

Published
2012
Full Text
View/download PDF

25. A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Author

Mékinian, Arsène, Zhao, Lin-Pierre, Desseaux, Kristell, Rose, Rose, Pascal, Laurent, Peterlin, Pierre, Comont, Thibault, Maria, Alexandre, Terriou, Louis, d'Aveni, Maud, Gourin, Marie-Pierre, Vey, Norbert, bayne Rouzy, Odile, Dimicoli Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, De Renzis, Benoit, Durot, Eric, Ame, Shanti, Voillat, Laurent, Chermat, Fatiha, Vekhoff, Anne, Lemaire, Karine, Jachiet, Vincent, Chevret, Sylvie, Ades, Lionel, Fain, Olivier, and Fenaux, Pierre

Published
2021
Full Text
View/download PDF

27. Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count.

Author

Divoux, Marion, Plocque, Alexia, Sevin, Margaux, Voillat, Laurent, Feugier, Pierre, Guerci‐Bresler, Agnès, Girodon, Francois, and Broséus, Julien

Subjects
PLATELET count, RED blood cell transfusion, CANCER
Abstract

Lenalidomide is efficient in reducing red blood cell transfusion dependency and markedly lowering platelet counts in MDS/MPN‐RS‐T in the context of major platelet counts. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.

Author

Sesques, Pierre, Bourcier, Jessie, Golfier, Camille, Lebras, Laure, Nicolas‐Virelizier, Emmanuelle, Hacini, Maya, Perrin, Marie Claire, Voillat, Laurent, Bachy, Emmanuel, Traverse‐Glehen, Alexandra, Moreau, Anne, Martin, Laurent, Ramla, Selim, Casasnovas, Olivier, Le Gouill, Steven, Salles, Gilles, Ghesquières, Hervé, Nicolas-Virelizier, Emmanuelle, and Traverse-Glehen, Alexandra

Subjects
STEM cell transplantation, LYMPHOMAS, PROGRESSION-free survival
Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a therapeutic option for patients with relapsed follicular lymphoma (FL). The clinical characteristics and outcomes of FL relapse after ASCT in the rituximab era have not yet been fully elucidated. We retrospectively reviewed 414 FL patients treated with ASCT between 2000 and 2014 in four hematology departments. All patients received rituximab as a first-line treatment. We specifically analyzed the clinical characteristics, treatment strategies at relapse, and outcomes of 95 patients (23%) who relapsed after ASCT. The patients (median age, 57 y) received a median of two lines of therapy (range, 2-6) prior to ASCT, with 92% in complete response (CR) or partial response (PR) before ASCT. Histological transformation at relapse after ASCT was observed in 20% of the patients. Treatment at relapse after ASCT consisted of chemotherapy with or without rituximab (n = 45/90, 50%), targeted agents (18%), rituximab monotherapy (14%), or consolidation allogeneic transplantation after induction chemotherapy (12%) and radiotherapy (6%). After relapse, the median progression-free survival (PFS) and overall survival (OS) were 1 year (95% CI, 0.541-1.579) and 5.5 years (95% CI, 1.910-9.099), respectively. In the multivariate analysis, histological transformation (HT) was associated with OS (P = .044; HR 2.439; 95% CI, 1.025-5.806), and a high FLIPI score at relapse was associated with PFS (P = .028; HR 2.469; 95% CI, 1.104-5.521). This retrospective study showed that the period of PFS of patients who relapsed after ASCT is short. A biopsy should be performed for these patients to document the HT. Our results indicate that new treatment strategies will need to be developed for these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

29. Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines

Author

Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne-Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Herve, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Abstract

Guidelines for monitoring multiple myeloma patients expressing light chains only (light chain multiple myeloma; LCMM) rely on measurements of the monoclonal protein in urine. Alternatively serum free light chain (sFLC) measurements have better sensitivity over urine methods, however, demonstration that improved sensitivity provides any clinical benefit is lacking. Here we compared the performance of serum and urine measurements in 113 (72κ, 41λ) newly diagnosed LCMM patients enrolled onto the IFM-2009 trial. All diagnostic samples (100%) had an abnormal κ/λ sFLC ratio, and involved (monoclonal) FLC (iFLC) expressed at levels deemed measurable for monitoring (≥100mg/L). By contrast, only 64% patients had measurable levels of the monoclonal protein (≥200mg/24h) in urine protein electrophoresis (UPEP). After 1 and 3 treatment cycles, iFLC remained elevated in 71% and 46% patients, respectively, whilst UPEP reported a positive result in 37% and 18%; all the patients with a positive UPEP at cycle 3 also had elevated iFLC levels. Importantly, elevated iFLC or an abnormal κ/λ sFLC ratio after 3 treatment cycles associated with poorer PFS (p=0.006 and p

Published
2016

30. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Author

Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Weil, Damien Roos, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, Facon, Thierry, Service d'Hématologie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Général de La Roche sur Yon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Henri Duffaut (Avignon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Chalon-sur-Saône William Morey, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Meaux, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Hématologie Clinique, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Jonchère, Laurent, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

WOS:000368020103223; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

31. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.

Author

Perrot, Aurore, Lauwers-Cances, Valérie, Tournay, Elodie, Hulin, Cyrille, Chretien, Marie-Lorraine, Royer, Bruno, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Fontan, Jean, Voillat, Laurent, Demarquette, Hélène, Collet, Philippe, Rodon, Philippe, Sohn, Claudine, Lifermann, François, Orsini-Piocelle, Frédérique, and Richez, Valentine

Published
2019
Full Text
View/download PDF

32. Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients

Author

M. Joao, Cristina, Plocque, Alexia, Richez, Valentine, Gay, Fransesca, Renaud, Loic, Legros, Laurence, Garderet, Laurent, Ikhlef, Souhila, Pegourie, Brigitte, Escoffre-Barbe, Martine, Royer, Bruno, Voillat, Laurent, Hulin, Cyrille, Banos, Anne, Vogg, Erik G., Karlin, Lionel, Stoppa, Anne-Marie, Benboubker, Lotfi, Zweegman, Sonja, De Jongh, Eve, Abildgaard , Niels, Le Du, Katell, J. Jurczyszyn, Artur, Moreau, Philippe, Facon, Thierry, Caillot, Denis, Terpos, Evangelos, and Leleu, Xavier

Published
2014

34. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, Fouquet, Guillemette, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Bourquard, Pascal, Lenain, Pascal, Roussel, Muriel, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Frayfer, Jamile, Fitoussi, Olivier, Roos Weil, Damien, Eisenmann, Jean-Claude, Dorvaux, Véronique, Voog, Eric, Hulin, Cyrille, and Attal, Michel

Published
2017
Full Text
View/download PDF

35. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Author

Weisel, Katja, Doyen, Chantal, Dimopoulos, Meletios, Yee, Adrian, Lahuerta, Juan José, Martin, Amber, Travers, Karin, Druyts, Eric, Toor, Kabirraaj, Abildgaard, Niels, Lu, Jin, Van Droogenbroeck, Jan, Geraldes, Catarina, Petrini, Mario, Voillat, Laurent, Voog, Eric, and Facon, Thierry

Subjects
MULTIPLE myeloma treatment, STEM cell transplantation, MELPHALAN, THALIDOMIDE, BORTEZOMIB, CANCER invasiveness, DRUG efficacy, TREATMENT effectiveness, THERAPEUTICS
Abstract

In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib (VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) for the combination of lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have compared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this analysis, Rd was associated with a significant PFS and survival advantage versus other first-line treatments (VMP, MPT, MP), challenging the role of alkylators in this setting. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma (eNDMM) from Thalidomide

Author

Demarquette, Hélène, Guidez, Stéphanie, Jurczyszyn, Artur J., Caillot, Denis, Pegourie, Brigitte, Chretien, Marie Lorraine, Lancesseur, Charles, Karlin, Lionel, Joao, Cristina M., Bories, Claire, Legros, Laurence, Garderet, Laurent, Ikhlef, Souhila, Escoffre, Martine, Royer, Bruno, Voillat, Laurent, Hulin, Cyrille, Banos, Anne, Voog, Eric G., Stoppa, Anne-Marie, Benboubker, Lofti, Abildgaard, Niels, Le Du, Katell, Moreau, Philippe, Facon, Thierry, Zweegman, Sonja, MACRO, Margaret, Gay, Francesca, Terpos, Evangelos, and Leleu, Xavier

Published
2015
Full Text
View/download PDF

38. Time to Spare Newly Diagnosed Non Transplant Eligible Myeloma from Thalidomide

Author

Caillot, Denis, Newingerm, Muriel, Macro, Margaret, Pegourie, Brigitte, Karlin, Lionel, Gay, Francesca, Bories, Claire, Legros, Laurence, Garderet, Laurent, Ikhlef, Souhila, Escoffre-Barbe, Martine, Royer, Bruno, Voillat, Laurent, Hulin, Cyrille, Banos, Anne, Voog, Eric G., Stoppa, Anne-Marie, Benboubker, Lotfi, De Jongh, Eva, Zweegman, Sonja, Abildgaard, Niels, Le Dû, Katell, Jurczyszyn, Artur J., Moreau, Philippe, Facon, Thierry, Terpos, Evangelos, Leleu, Xavier, Vieira Dos Santos, Catherine, and Demarquette, Helene

Published
2014
Full Text
View/download PDF

40. Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients

Author

Herbaux, Charles, Joao, Cristina M., Plocque, Alexia, Richez, Valentine, Gay, Francesca, Renaud, Loic, Legros, Laurence, Garderet, Laurent, Ikhlef, Souhila, Pegourie, Brigitte, Escoffre-Barbe, Martine, Royer, Bruno, Voillat, Laurent, Hulin, Cyrille, Banos, Anne, Voog, Eric G., Karlin, Lionel, Stoppa, Anne-Marie, Benboubker, Lotfi, Zweegman, Sonja, De Jongh, Eva, Abildgaard, Niels, Le Dû, Katell, Jurczyszyn, Artur J., Moreau, Philippe, Facon, Thierry, Caillot, Denis, Terpos, Evangelos, and Leleu, Xavier

Published
2014
Full Text
View/download PDF

41. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

Author

Leleu, Xavier, Rodon, Philippe, Hulin, Cyrille, Daley, Laurent, Dauriac, Charles, Hacini, Maya, Decaux, Olivier, Eisemann, Jean-Claude, Fitoussi, Olivier, Lioure, Bruno, Voillat, Laurent, Slama, Borhane, Jijakli, Ahmad Al, Benramdane, Riad, Chaleteix, Carinne, Costello, Régis, Thyss, Antoine, Mathiot, Claire, Boyle, Eileen, and Maloisel, Frédéric

Published
2013
Full Text
View/download PDF

42. Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience.

Author

Avet-Loiseau, Hervé, Hulin, Cyrille, Campion, Loic, Rodon, Philippe, Marit, Gerald, Attal, Michel, Royer, Bruno, Dib, Mamoun, Voillat, Laurent, Bouscary, Didier, Caillot, Denis, Wetterwald, Marc, Pegourie, Brigitte, Lepeu, Gerard, Corront, Bernadette, Karlin, Lionel, Stoppa, Anne-Marie, Fuzibet, Jean-Gabriel, Delbrel, Xavier, and Guilhot, Francois

Published
2013
Full Text
View/download PDF

43. Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial.

Author

Damaj, Gandhi, Gressin, Rémy, Bouabdallah, Krimo, Cartron, Guillaume, Choufi, Bachra, Gyan, Emmanuel, Banos, Anne, Jaccard, Arnaud, Park, Sophie, Tournilhac, Olivier, Collela, Jean-Marc Schiano-de, Voillat, Laurent, Joly, Bertrand, Le Gouill, Steven, Saad, Alain, Cony-Makhoul, Pascale, Vilque, Jean-Pierre, Sanhes, Laurence, Schmidt-Tanguy, Aline, and Bubenheim, Michael

Published
2013
Full Text
View/download PDF

44. The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease

Author

Moreau, Philippe, Planche, Lucie, Attal, Michel, Hulin, Cyrille, Facon, Thierry, Caillot, Denis, Marit, Gerald, Benboubker, Lotfi, Stoppa, Anne-Marie, Michallet, Mauricette, Garderet, Laurent, Casassus, Philippe, Pegourie, Brigitte, Kolb, Brigitte, Voillat, Laurent, Lioure, Bruno, Roussel, Murielle, Touzeau, Cyrille, Leleu, Xavier, Harousseau, Jean-Luc, Avet-Loiseau, Herve, and Mary, Jean-Yves

Published
2012
Full Text
View/download PDF

45. Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience

Author

Hulin, Cyrille, Rodon, Philippe, Campion, Loic, Roussel, Murielle, Leleu, Xavier, Marit, Gerald, Caillot, Denis, Royer, Bruno, Kolb, Brigitte, Dib, Mamoun, Voillat, Laurent, Pegourie, Brigitte, Wetterwald, Marc, Garderet, Laurent, Benboubker, Lotfi, Decaux, Olivier, Chaleteix, Carine, Traulle, Catherine, Macro, Margaret, Moreau, Philippe, and avet-Loiseau, Herve

Published
2012
Full Text
View/download PDF

46. Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study

Author

Hebraud, Benjamin, Caillot, Denis, Corre, Jill, Marit, Gerald, Hulin, Cyrille, Leleu, Xavier, Wetterwald, Marc, Dib, Mamoun, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Voog, Eric G., Stoppa, Anne-Marie, Garderet, Laurent, Kolb, Brigitte, Maigre, Michel, Nadine, Boullanger FOW HENG, Allangba, Olivier, Facon, Thierry, Mathiot, Claire, Attal, Michel, Moreau, Philippe, and avet-Loiseau, Herve

Published
2012
Full Text
View/download PDF

47. Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival.

Author

Avet-Loiseau, Hervé, Attal, Michel, Campion, Loic, Caillot, Denis, Hulin, Cyrille, Marit, Gerald, Stoppa, Anne-Marie, Voillat, Laurent, Wetterwald, Marc, Pegourie, Brigitte, Voog, Eric, Tiab, Mourad, Banos, Anne, Jaubert, Jerome, Bouscary, Didier, Macro, Margaret, Kolb, Brigitte, Traulle, Catherine, Mathiot, Claire, and Magrangeas, Florence

Published
2012
Full Text
View/download PDF

48. Final Analysis of MELISSE, a Large Multicentric Observational Study to Determine Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Treated with Immunomodulator Drugs

Author

Leleu, Xavier, Daley, Laurent, Rodon, Philippe, Hulin, Cyrille, Dauriac, Charles, Hacini, Hacini, Decaux, Olivier, Eisemann, Jean-Claude, Fitoussi, Olivier, Voillat, Laurent, Slama, Borhane, Jijakli, Ahmad Al, Chaleteix, Carinne, Costello, Régis, Lamblin, Anne, Natta, Patrick, Fermand, Jean Paul, and Moreau, Philippe

Published
2011
Full Text
View/download PDF

50. Melphalan-Prednisone-Thalidomide (MP-T) Demonstrates a Significant Survival Advantage in Elderly Patients ≥75 Years with Multiple Myeloma Compared with Melphalan-Prednisone (MP) in a Randomized, Double-Blind, Placebo-Controlled Trial, IFM 01/01.

Author

Hulin, Cyrille, Facon, Thierry, Rodon, Philippe, Pegourie, Brigitte, Benboubker, Lotfi, Doyen, Chantal, Dib, Mamoun, Guillerm, Gael, Voillat, Laurent, Mathiot, Claire, Casassus, Philippe, Decaux, Olivier, Flesch, Michel, Garderet, Laurent, and Moreau, Philippe

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results